Log in

NASDAQ:POAIPrecision Therapeutics Stock Price, Forecast & News

$1.67
+0.11 (+7.05 %)
(As of 08/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.56
Now: $1.67
$1.79
50-Day Range
$1.44
MA: $1.64
$1.99
52-Week Range
$1.25
Now: $1.67
$6.80
Volume2.29 million shs
Average Volume1.12 million shs
Market Capitalization$24.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:POAI
CUSIPN/A
Phone651-389-4800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.41 million
Book Value$2.76 per share

Profitability

Net Income$-19,390,000.00
Net Margins-1,420.59%

Miscellaneous

Employees24
Market Cap$24.22 million
Next Earnings Date8/17/2020 (Estimated)
OptionableNot Optionable
$1.67
+0.11 (+7.05 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive POAI News and Ratings via Email

Sign-up to receive the latest news and ratings for POAI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Precision Therapeutics (NASDAQ:POAI) Frequently Asked Questions

How has Precision Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Precision Therapeutics' stock was trading at $2.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, POAI shares have decreased by 22.0% and is now trading at $1.67.
View which stocks have been most impacted by Coronavirus
.

When is Precision Therapeutics' next earnings date?

Precision Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020.
View our earnings forecast for Precision Therapeutics
.

How were Precision Therapeutics' earnings last quarter?

Precision Therapeutics Inc (NASDAQ:POAI) released its earnings results on Monday, June, 8th. The medical instruments supplier reported ($0.93) earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $0.30 million for the quarter. Precision Therapeutics had a negative net margin of 1,420.59% and a negative return on equity of 73.02%.
View Precision Therapeutics' earnings history
.

Has Precision Therapeutics been receiving favorable news coverage?

Media stories about POAI stock have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Precision Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days.
View the latest news about Precision Therapeutics
.

Are investors shorting Precision Therapeutics?

Precision Therapeutics saw a decline in short interest in July. As of July 15th, there was short interest totaling 172,900 shares, a decline of 7.4% from the June 30th total of 186,800 shares. Based on an average daily trading volume, of 1,150,000 shares, the short-interest ratio is presently 0.2 days. Currently, 1.6% of the company's stock are short sold.
View Precision Therapeutics' Current Options Chain
.

Who are some of Precision Therapeutics' key competitors?

What other stocks do shareholders of Precision Therapeutics own?

Who are Precision Therapeutics' key executives?

Precision Therapeutics' management team includes the following people:
  • Dr. Carl I. Schwartz, CEO & Director (Age 78)
  • Mr. Robert L. Myers, CFO & Sec. (Age 64)
  • Mr. David Orrin Johnson, Sr. VP of Operations - Skyline Medical Bus. Unit (Age 66)
  • Mr. Kevin Hungerford, VP of Sales & Marketing

What is Precision Therapeutics' stock symbol?

Precision Therapeutics trades on the NASDAQ under the ticker symbol "POAI."

Who are Precision Therapeutics' major shareholders?

Precision Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Csenge Advisory Group (0.13%). Company insiders that own Precision Therapeutics stock include Carl I Schwartz and Richard L Gabriel.
View institutional ownership trends for Precision Therapeutics
.

Which major investors are buying Precision Therapeutics stock?

POAI stock was purchased by a variety of institutional investors in the last quarter, including Csenge Advisory Group. Company insiders that have bought Precision Therapeutics stock in the last two years include Carl I Schwartz, and Richard L Gabriel.
View insider buying and selling activity for Precision Therapeutics
.

How do I buy shares of Precision Therapeutics?

Shares of POAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precision Therapeutics' stock price today?

One share of POAI stock can currently be purchased for approximately $1.67.

How big of a company is Precision Therapeutics?

Precision Therapeutics has a market capitalization of $24.22 million and generates $1.41 million in revenue each year. Precision Therapeutics employs 24 workers across the globe.

What is Precision Therapeutics' official website?

The official website for Precision Therapeutics is www.precisiontherapeutics.com.

How can I contact Precision Therapeutics?

Precision Therapeutics' mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The medical instruments supplier can be reached via phone at 651-389-4800 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.